These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Integration of Receptor Tyrosine Kinases Determines Sensitivity to PI3Kα-selective Inhibitors in Breast Cancer. Xu YC; Wang X; Chen Y; Chen SM; Yang XY; Sun YM; Geng MY; Ding J; Meng LH Theranostics; 2017; 7(4):974-986. PubMed ID: 28382169 [TBL] [Abstract][Full Text] [Related]
7. Receptor Tyrosine Kinases in Osteosarcoma Treatment: Which Is the Key Target? Tian Z; Niu X; Yao W Front Oncol; 2020; 10():1642. PubMed ID: 32984034 [TBL] [Abstract][Full Text] [Related]
8. Receptor Tyrosine Kinase Expression Profiles in Canine Cutaneous and Subcutaneous Mast Cell Tumors. Thompson JJ; Morrison JA; Pearl DL; Boston SE; Wood GA; Foster RA; Coomber BL Vet Pathol; 2016 May; 53(3):545-58. PubMed ID: 26459517 [TBL] [Abstract][Full Text] [Related]
9. Multiple receptor tyrosine kinases promote the in vitro phenotype of metastatic human osteosarcoma cell lines. Rettew AN; Young ED; Lev DC; Kleinerman ES; Abdul-Karim FW; Getty PJ; Greenfield EM Oncogenesis; 2012 Nov; 1(11):e34. PubMed ID: 23552467 [TBL] [Abstract][Full Text] [Related]
10. Targeting the E3 ubiquitin casitas B-lineage lymphoma decreases osteosarcoma cell growth and survival and reduces tumorigenesis. Sévère N; Dieudonné FX; Marty C; Modrowski D; Patiño-García A; Lecanda F; Fromigué O; Marie PJ J Bone Miner Res; 2012 Oct; 27(10):2108-17. PubMed ID: 22623369 [TBL] [Abstract][Full Text] [Related]
11. Inhibition of c-Met activation sensitizes osteosarcoma cells to cisplatin via suppression of the PI3K-Akt signaling. Wang K; Zhuang Y; Liu C; Li Y Arch Biochem Biophys; 2012 Oct; 526(1):38-43. PubMed ID: 22820099 [TBL] [Abstract][Full Text] [Related]
12. Receptor Tyrosine Kinases: Principles and Functions in Glioma Invasion. Nakada M; Kita D; Teng L; Pyko IV; Watanabe T; Hayashi Y; Hamada JI Adv Exp Med Biol; 2020; 1202():151-178. PubMed ID: 32034713 [TBL] [Abstract][Full Text] [Related]
13. Coactivation of receptor tyrosine kinases in malignant mesothelioma as a rationale for combination targeted therapy. Brevet M; Shimizu S; Bott MJ; Shukla N; Zhou Q; Olshen AB; Rusch V; Ladanyi M J Thorac Oncol; 2011 May; 6(5):864-74. PubMed ID: 21774103 [TBL] [Abstract][Full Text] [Related]
14. Tyrosine kinase receptor-activated signal transduction pathways which lead to oncogenesis. Porter AC; Vaillancourt RR Oncogene; 1998 Sep; 17(11 Reviews):1343-52. PubMed ID: 9779982 [TBL] [Abstract][Full Text] [Related]
15. Receptor tyrosine kinases: principles and functions in glioma invasion. Nakada M; Kita D; Teng L; Pyko IV; Watanabe T; Hayashi Y; Hamada J Adv Exp Med Biol; 2013; 986():143-70. PubMed ID: 22879068 [TBL] [Abstract][Full Text] [Related]
16. The tyrosine kinase CSK associates with FLT3 and c-Kit receptors and regulates downstream signaling. Kazi JU; Vaapil M; Agarwal S; Bracco E; Påhlman S; Rönnstrand L Cell Signal; 2013 Sep; 25(9):1852-60. PubMed ID: 23707526 [TBL] [Abstract][Full Text] [Related]
17. Evaluating the landscape of gene cooperativity with receptor tyrosine kinases in liver tumorigenesis using transposon-mediated mutagenesis. Fan Y; Bazai SK; Daian F; Arechederra M; Richelme S; Temiz NA; Yim A; Habermann BH; Dono R; Largaespada DA; Maina F J Hepatol; 2019 Mar; 70(3):470-482. PubMed ID: 30529386 [TBL] [Abstract][Full Text] [Related]
18. Adaptive responses to antibody based therapy. Rodems TS; Iida M; Brand TM; Pearson HE; Orbuch RA; Flanigan BG; Wheeler DL Semin Cell Dev Biol; 2016 Feb; 50():153-63. PubMed ID: 26808665 [TBL] [Abstract][Full Text] [Related]
19. Synthesis and biological evaluations of 3-substituted indolin-2-ones: a novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases. Sun L; Tran N; Tang F; App H; Hirth P; McMahon G; Tang C J Med Chem; 1998 Jul; 41(14):2588-603. PubMed ID: 9651163 [TBL] [Abstract][Full Text] [Related]
20. Resistance mediated by alternative receptor tyrosine kinases in FGFR1-amplified lung cancer. Adachi Y; Watanabe K; Kita K; Kitai H; Kotani H; Sato Y; Inase N; Yano S; Ebi H Carcinogenesis; 2017 Oct; 38(11):1063-1072. PubMed ID: 28968756 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]